Patient recieving home parenteral nutrition: * Transition from nocturnal PN to daytime PN (9 AM to 9 PM) for 4 consecutive days.
* A four-day washout period where the nocturnal PN (9PM to 9AM) regimen is reinstated.
* A final 4-day phase where melatonin supplementation (0.5 mg sublingual drops at 8 PM) is introduced while maintaining nocturnal PN.
Study summary
Medical Nutritional Therapy (MNT) is critical for patients with impaired oral intake and is typically administered via parenteral nutrition (PN). Current infusion practices-nocturnal home parenteral nutrition (NHPN)-may induce circadian misalignment (chronodisruption). This misalignment can negatively impact metabolic function, sleep quality, and overall quality of life for both patients and caregivers. Synchronising MNT administration with circadian rhythms may improve metabolic balance, sleep, and patient well-being.
Hypothesis: The timing of the administration of Medical Nutritional Therapy via nocturnal home parenteral nutrition (NHPN) in outpatients may induce chronodisruption in biological rhythms (clock genes). This disruption can affect the metabolism of carbohydrates, lipids, and proteins, contributing to morbidity and altering chronotype, quality of life, and sleep patterns.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants must have been receiving nighttime home parenteral nutrition (NPN) for at least two consecutive months.
Referred from the Regional University Hospital of Málaga (HRUM), Virgen del Rocío Hospital of Seville (HVR), Reina Sofía University Hospital of Córdoba, or the NUPA Association.
* Participants must not have suffered any recent acute illnesses.
* Participants must not have been hospitalized, received transfusions, or visited the emergency room in the last month.
* Participants must not have made significant changes to their diet or physical activity during the last two months.
* Participants must provide informed consent (patient or legal representative).
* Participants must be able to answer the questionnaires.
* Participants must be metabolically and clinically stable.
Exclusion Criteria:
* Known sleep or circadian rhythm disorders.
* Use of melatonin for sleep.
Primary outcome measure(s)
Changes in Circadian Gene Expression — From baselilne to 24 hours for 4 days Measurement of mRNA expression levels of clock genes (via RT-PCR from oral mucosa samples)
Changes in Hormonal Rhythmicity - melatonin — From baselilne to 24 hours for 4 days Melatonin measured in pg/ml in saliva
Changes in Hormonal Rhythmicity - cortisol — From baselilne to 24 hours for 4 days Cortisol measured in µg/dl in saliva
Trial sites (1)
Facility
City
Region
Status
Hospital Regional Universitario de Málaga, FIMABIS
Málaga
Málaga
Recruiting
More Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.